Study of relatlimab in combination with nivolumab in first-line treatment of metastatic or unresectable melanoma meets primary endpoint

In the Phase 2/3 RELATIVITY-047 study (n=714), relatlimab (anti-LAG-3 antibody) in combination with nivolumab was associated with increased progression-free survival vs nivolumab alone (no results reported). Follow-up for overall survival is ongoing.

Source:

Biospace Inc.